tkmr 四种新药2016进临床

newchinabok

PhillyVoice
Search MenuBUSINESS
NEWS
BUSINESS
ENTERTAINMENT
FOOD & DRINK
SPORTS
from   SOURCE/FILE ART Prescription drugs
AUGUST 03, 2015

Doylestown researchers close in on hepatitis B treatment

Human testing on four experimental treatments expected to begin next year

BIOTECHNOLOGY HEPATITIS B DOYLESTOWN TREATMENTS HEALTH SOLVALDI ARBUTUS BIOPHARMA HEPATITIS C BUCKS COUNTY
BY SHARON LURYE
PhillyVoice Staff
Just two years after the Food and Drug Administration approved a drug that cures hepatitis C, a Bucks County research company has said that it is close to beginning human testing for a treatment for hepatitis B, the Philadelphia Business Journal reported.

Arbutus BioPharma Corp., a company that formed from the merger of OnCore BioPharma in Doylestown and Tekmira Pharmaceuticals in Vancouver, Canada, said that it hopes to begin human trials on four experimental hepatitis B treatments within the first half of 2016.

Hepatitis B is a liver virus that affects 12 million people in the U.S. and 400 million people worldwide. It differs from hepatitis C in that it is easier to transmit from mother to child during pregnancy, meaning that many people are infected as infants, the New Yorker said.

On board is Chief Scientific Officer Michael Sofia, who helped invent the cure for hepatitis C at the biotech firm Pharmasett in Princeton, New Jersey. Gilead Sciences paid $11 billion to acquire Pharmasett and made more than $10 billion in sales of the hepatitis C drug, Solvaldi, in 2014 alone.


Sofia told the Business Journal in March, “It’s very rare that people in this business get involved in a significant way with a drug that you know is going to have such a big impact – curing a disease. Many drugs treat a disease, but when you cure a disease, that’s something else.”

And curing two diseases? That’s something else again.

newchinabok

Doylestown人员接近乙肝治疗
人体试验在四个实验治疗预计将于明年开始
生物技术治疗乙型肝炎DOYLESTOWN健康SOLVALDI杨梅生物制药丙型肝炎雄鹿县
通过沙龙LURYE
PhillyVoice员工
仅仅两年前,美国食品和药物管理局批准的药物治疗丙型肝炎,雄鹿县研究公司已表示,它已接近开始人体试验治疗乙型肝炎,费城商业日报》报道。
杨梅生物制药公司,公司合并成立OnCore生物制药在美国多伊尔斯敦和Tekmira制药在温哥华,加拿大表示,它希望开始人体试验四个实验在2016年上半年的乙肝治疗方法。
乙型肝炎是一种肝脏病毒影响1200万人在美国和全世界4亿人。与丙型肝炎的不同之处在于,它更容易从孕期母婴传播,这意味着很多人感染婴儿,《纽约客》说。
船上是首席科学官迈克尔·索菲亚发明了治疗丙型肝炎的生物技术公司Pharmasett在普林斯顿,新泽西。基列科学斥资110亿美元收购Pharmasett和超过100亿美元的销售额丙型肝炎的药物,Solvaldi,仅2014年一年。
索菲亚告诉《商业日报》3月”,这是非常罕见的,人们在这个行业参与一个重要的方法和药物,你知道会有这么大的影响——治愈疾病。许多药物治疗疾病,但是当你治愈疾病,这是别的东西。”

newchinabok

Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company

Four HBV Product Candidates Advancing In Human Clinical Trials in 1H16

Three IND Filings in 2016 for Oral HBV Drug Candidates Targeting cccDNA, S-Antigen, and Core Protein

New Business Unit Established to Maximize Value of Tekmira's Non-HBV Assets

newchinabok

Three IND Filings in 2016 for Oral HBV Drug Candidates Targeting cccDNA, S-Antigen, and Core Protein

重韧

还是看好有Oncore在里面的TEK 的新药，感觉更靠谱一些。

newchinabok

不好说，只能谨慎乐观，乙肝动物模型不好，影响化学药的开发，莫非赛定就是例子

zgct

好文

ZDWAAA

莫非赛定现在怎样？

newchinabok

不中了，去球了

ZDWAAA

乙肝动物模型不好，影响化学药的开发，莫非赛定就是例子。这到底是怎么回事？